| 100.95 BATS BZX Real-Time Price As of 1:39pm ET |  +0.12 / +0.12%Today’s Change | 64.72 Today|||52-Week Range 125.59 | +41.37% Year-to-Date |
| Buy These 7 Small Drugmakers to Boost Your Portfolio's Health Sep 18 / Zacks.com - Paid Partner Content | HKMPF vs. NBIX: Which Stock Should Value Investors Buy Now? Sep 05 / Zacks.com - Paid Partner Content |
| Previous close | 100.83 |
| Today’s open | 101.05 |
| Day’s range | 100.23 - 101.93 |
| Volume | 276,139 |
| Average volume (3 months) | 661,700 |
| Market cap | $9.2B |
| Earnings growth (last year) | -- |
| Earnings growth (this year) | +313.16% |
| Earnings growth (next 5 years) | +35.00% |
| Revenue growth (last year) | +179.19% |
| P/E ratio | 530.5 |
| Price/Sales | 15.10 |
| Price/Book | 19.04 |
| Today’s change | Today’s % change | |
|---|---|---|
| TECHBio-Techne Corp | +1.16 | +0.58% |
| MRNAModerna Inc | -0.23 | -1.27% |
| BLUEbluebird bio Inc | -1.03 | -0.96% |
| BMRNBiomarin Pharmaceuti... | -1.05 | -1.40% |
| Next reporting date | October 30, 2019 |
| EPS forecast (this quarter) | $0.65 |
| Annual revenue (last year) | $451.2M |
| Annual profit (last year) | $21.1M |
| Net profit margin | 4.68% |
Sector Health Technology |
Industry Biotechnology |
Chief Executive Officer & Director Kevin Charles Gorman |
Chief Financial Officer Matthew C. Abernethy |
Corporate headquarters San Diego, California |
